Cord Blood News 9.31 August 10, 2017 | |
| |
TOP STORYScientists studied the intervention effects of clinical-grade human umbilical cord-derived (hUC)-MSCs on cognitive aging in a murine model of aging. After three months of systematical regulation of hUC-MSCs, the hippocampal-dependent learning and memory ability was effectively improved in aged mice. [Cell Death Dis] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)CD71+ Erythroid Suppressor Cells Impair Adaptive Immunity against Bordetella pertussis The authors observed that CD71+ cells have distinctive immunosuppressive properties and prevent recruitment of immune cells to the mucosal site of infection. CD71+ cells ablation unleashed induction of B. pertussis-specific protective cytokines in the lungs and spleen upon re-infection or vaccination. They found that human cord blood CD71+ cells also suppressed T and B cell functions in vitro. [Sci Rep] Full Article Evidence for a Role of TRIB3 in the Regulation of Megakaryocytopoiesis Using cellular model systems of hematopoietic lineage differentiation, investigators demonstrated that the tribbles pseudokinase 3 gene (TRIB3) is a negative modulator of megakaryocytopoiesis. They found that in primary cultures derived from human hematopoietic progenitor cells, thrombopoietin-induced megakaryocytic differentiation led to a time and dose-dependent decrease in TRIB3 mRNA levels. [Sci Rep] Full Article Scientists explored the effects of lysophosphatidic acid (LPA) on the survival and differentiation of MSCs and its availability in cell therapy. They found that LPA stimulated human umbilical cord (hUC)-MSC proliferation and protected hUC-MSCs from lipopolysaccharide induced apoptosis. [Apoptosis] Full Article Transient overexpressing miR342-3p in human umbilical MSCs via miR-342-3p mimicked dramatically decreased suppressor-of-fused protein (Sufu), a suppressor of Gli, while osteogenic markers, including alkaline phosphate and osteocalcin, were upregulated during osteogenic induction, indicating that miR-342-3p might be involved in osteogenesis through the sonic hedgehog signaling pathway. [Biochem Biophys Res Commun] Abstract Researchers found that hypoxia could promote umbilical cord MSC differentiation into type II alveolar epithelial cells rather than into fibroblast-like cells, and this effect was mainly mediated by miR-145, which could induce the inhibition of transforming growth factor-β (TGF-β) signaling by targeting TGF-β receptor II. [Gene] Abstract An insufficient number of hematopoietic stem cells (HSCs) in umbilical cord blood (UCB) is still a major constraint in clinical applications. In vitro expansion of stem cells on a fibronectin (Fn)-coated PLLA scaffold could be a proper way to overcome this limitation. After seven days, there were higher numbers of CD133+cells on the Fn-coated PLLA scaffold compared to other groups. [Artif Cells Nanomed Biotechnol] Abstract | |
| |
REVIEWSThe Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia The authors review the safety of bosutinib in the treatment of chronic phase chronic myeloid leukemia. The data was extracted from the latest updates of bosutinib Phase I/II and III trials. [Expert Opin Drug Saf] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSSelvita S.A. and The Leukemia & Lymphoma Society announced a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia (AML). Selvita has discovered and is developing SEL120, a therapy that targets the cyclin-dependent kinase 8 protein, which plays a unique and critical role in gene regulation. [Selvita S.A.] Press Release Helsinn and MEI Pharma, Inc. announced that the first patient has been dosed in the pivotal Phase III study of the investigational agent pracinostat in combination with azacitidine in adults with newly diagnosed acute myeloid leukemia who are unfit to receive intensive induction chemotherapy. [MEI Pharma, Inc.] Press Release Kite Pharma, Inc. announced that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma are now being treated in its Phase II ZUMA-5 trial with its lead investigational candidate, axicabtagene ciloleucel. [Kite Pharma, Inc.] Press Release | |
| |
POLICY NEWSThousands across India March in Support of Science Thousands of scientists, university students and science enthusiasts gathered in dozens of Indian cities to march in support of science — lamenting their country’s low levels of funding for research, and complaining about government promotion of ‘unscientific ideas’. [Nature News] Editorial FDA Cracks Down on Pioneering Doctor Who Created a Three-Parent Baby The New York-based doctor who helped a couple have a child using DNA from three people has been told by the FDA that he can’t go ahead with clinical trials meant to test the technique. [MIT Technology Review] Editorial CRISPR Patent Battle in Europe Takes a ‘Wild’ Twist with Surprising Player MilliporeSigma, a subsidiary of pharmaceutical giant Merck KGaA of Darmstadt, Germany, has become a new major player in the complicated European patent battles over CRISPR, the revolutionary genome-editing tool. [ScienceInsider] Editorial Chronic Diseases Spike in Middle East as Conflicts Rage Across the Middle East, deaths resulting from violence grew by 850% between 1990 and 2015, according to a series of reports published in the International Journal of Public Health. The increase accelerated after 2010, corresponding with the beginning of the Arab Spring movement and wars in Syria and Iraq. At the same time, the authors found, the incidence of many chronic diseases has also risen dramatically. [Nature News] Editorial Discredited Gene-Editing Researcher Vows to Clear His Name A Chinese biologist whose team retracted a high-profile paper on a gene-editing technology has vowed to press ahead with experiments that he hopes will vindicate the potential rival to the CRISPR/Cas9 system. [ScienceInsider] Editorial
| |
EVENTSNEW International Vascular Biology Meeting (IVBM) 2018 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESProduction Manager – Blood and Related Transfusion Products (Blood Systems Research Institute) Researcher – Acute Myeloid Leukemia Research (University of Perugia) Assistant Professor – Stem Cell and Regenerative Biology (Harvard University) Postdoctoral Position – Cell Biology (The Scripps Research Institute) Postdoctoral Fellow – Hematopoietic & Mesenchymal Stem Cells (Loma Linda University) Postdoctoral Associate – Normal & Malignant Hematopoiesis (University of Miami) Postdoctoral Position – Acute Myeloid Leukemia (University Hospital Heidelberg) Postdoctoral Researcher – Acute Myeloid Leukemia (Ohio State University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Cord Blood News Volume 9.31 | Aug 10 2017